NICE - early BC and Paclitaxel and Docetaxel
NICE - early BC and Paclitaxel and Docetaxel If you wish to comment on the draft appraisals on the above drugs NICE would like to hear from you (I’ve not read what has been produced yet).
Follow links on the NICE website.
Sandra
My thoughts It seems like neither is likely to be licenced because the drugs companies haven’t done the necessary experiments. They have been so focussed on proving that their taxanes can improve on the standard U.S. treatment, AC chemo, that they haven’t done the big comparisons against FEC.
However, Sanofi-Aventis does seem to have done a trial of FEC100 followed by taxotere that would be considered very cost effective (£8,200 per quality adjusted life year (QALY)) but NICE won’t consider it because Sanofi-Aventis haven’t gotten this treatment licenced in the UK first. Doh! Sanofi-Aventis.
My comment to NICE was that I wanted them to reconsider taxotere before 2009 because Sanofi-Aventis should have gotten the licence well before then and it wouldn’t be fair on breast cancer patients to be denied a cost-effective treatment for so long, since many PCTs won’t do anything that NICE doesn’t o.k.